Kendler, D. L, McClung, M. R, Freemantle, N., Lillestol, M., Moffett, A. H, Borenstein, J., Satram-Hoang, S., Yang, Y., Kaur, P., Macarios, D. & Siddhanti, S. (2011). Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporosis International,22(6), 1725-1735. United Kingdom: Springer UK. Retrieved from https://doi.org/10.1007/s00198-010-1378-z
In this study, 250 women with osteoporosis were randomized to 12 months with subcutaneous denosumab 60 mg every 6 months or oral alendronate 70 mg once weekly, then crossed over to the other treatment. The primary endpoint, treatment adherence at 12 months, was 76.6% for alendronate and 87.3% for denosumab.
Institute for Health and Ageing
Access may be restricted.